Starting Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC Did Not Improve Outcomes: PACIFIC-2 Recalibrates the Timing of Immunotherapy

Highlight

• In PACIFIC-2, initiating durvalumab at the start of definitive concurrent platinum-based chemoradiotherapy (cCRT) for unresectable stage III non–small cell lung cancer (NSCLC) did not improve progression-free survival (PFS) or overall survival (OS) versus placebo.

• Confirmed objective response rates were identical between arms (≈61%); rates of any pneumonitis were similar, but treatment discontinuations and fatal adverse events were numerically higher with upfront durvalumab.